Key facts
- Marginum’s last known valuation is $4.7M (Nov 2023).
- It has raised $6.8M; the latest was Later Stage VC ($2.9M) in Aug 2025.
- Notable investors include Redstone VC, Almaral, Business Center Pohjois Savo, DRAFT Karelia, Lynx Financial — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Marginum
- ·The full record, as it builds
Funding rounds
No funding rounds for Marginum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Marginum
Developer of tissue detection systems designed to help medical professionals treat cancer in patients. The company's systems improve the detection of cancer cells using new data-driven technologies and products derived from research, enabling clients to promote surgical performance and the cost-effectiveness of healthcare.
- Sector
- Healthcare
- HQ
- Kuopio, Finland
- Founded
- 2019
- Employees
- 10
- Website
- marginum.com/
- Ownership
- Privately Held (backing)
Marginum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Marginum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Marginum in its N-PORT filings yet. We sweep new filings monthly.